VivoSeq
Neurology

Radiculopathy

32

Pipeline Programs↗

5

Active Trials↗

18

Companies Involved↗

Radiculopathy is a moderately active landscape with 32 programs across 18 companies. The most active players are Vertex Pharmaceuticals, Medtronic Spinal and Biologics, Biogen. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

11/100

Mech. Concentration

29/100

Completion Rate

61/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2M

Medtronic Spinal and Biologics

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2GSK logo

GSK

1 program

Phase 2I

Immunex

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Gadolinium

OHSU Knight Cancer Institute

Clonidine

Boehringer Ingelheim

Triamcinolone Hexacetonide

Ethypharm

Lidocaine Hcl

Mayo Clinic

Acetaminophen Only

Taipei Medical University WanFang Hospital

Phase 13

Lidocaine

MEDRx USA, Inc.

C-1101

Consano Bio

VVZ-149

Vivozon, Inc.

Phase 29

Etanercept

Immunex

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Methylprednisolone

Pfizer

Dexamethasone

Aspen Global Incorporated

VX-548

Vertex Pharmaceuticals

Phase 36

Diclofenac Sodium

Cerimon Pharmaceuticals

Clonidine Micropellets

Sollis Therapeutics, Inc.

SP-102

Scilex Pharmaceuticals, Inc.

Voltaren

Novartis

Neuromultivit

Bausch Health Americas, Inc.

Approved9

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cannabidiol

Jazz Pharmaceuticals

Bupivacaine

Innocoll

Pentoxifylline

Validus Pharmaceuticals

Triamcinolone

Bassett Healthcare

Analysis

Modality Breakdown

97%

Small molecule

38 of 39 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme13%

Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 100% of 39 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed11 · 41%
Terminated6 · 22%
Unknown status4 · 15%
Recruiting3 · 11%
Enrolling by invitation1 · 4%
Active, not recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
Recruiting·CConsano Bio·Phase 1·NCT07264270·24 enrolled
Effect of High-Power Laser Therapy on Disc Morphology and Functional Outcome in Patients With Cervical Radiculopathy
Recruiting·CCairo University·Preclinical·NCT07661290·60 enrolled
Interest of the Virtual Reality as an Analgesic Support and in the Management the Pre-procedural Anxiety in Rheumatology
Recruiting·CCentre Hospitalier le Mans·Preclinical·NCT05289999·70 enrolled
Pentoxifylline and Lumbar Radiculopathy
Active, not recruiting·SSt Joseph University, Beirut, Lebanon·Phase 4·NCT03060434·67 enrolled
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
Enrolling by invitation·MMedical University of South Carolina·N/A·NCT06540456·50 enrolled
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
Completed·SScilex Pharmaceuticals, Inc.·Phase 3·NCT03372161·401 enrolled
Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica)
Completed·—·Phase 1·NCT02644421·18 enrolled
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
Completed·Biogen logoBiogen·Phase 2·NCT01873404·183 enrolled
Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy
Completed·BBausch Health Americas, Inc.·Phase 3·NCT02508805·100 enrolled
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy
Completed·ZZalicus·Phase 2·NCT01655849·141 enrolled
Cervical Retrolaminar Block Versus Cervical Epidural Injection for Cervical Radiculopathy
Completed·IIstanbul Medeniyet University·N/A·NCT07275320·70 enrolled
Efficacy Study in Lumbosacral Radiculopathy
Completed·GSK logoGSK·Phase 2·NCT01110057·142 enrolled
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2/3·NCT00120120·181 enrolled
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
Completed·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT06176196·218 enrolled
A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy
Completed·MMedtronic Spinal and Biologics·Phase 2·NCT01917825·54 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)